

Date E-filed: June 1, 2007

Sheet 2 of 4

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 09424.0238USWO	Application Number: 10/581,611
	Applicant: BERNIS et al.	
	Filing Date: June 5, 2006	Group Art Unit: Unknown

		Dowsett, 2004, <i>Breast Cancer Research and Treatment</i> , 87:1, pp. S11-S18 "Biomarker investigations from the ATAC trial: the role of TA01"
		Ferrero-Pous et al., Dec. 2000, <i>Clin. Cancer Res.</i> , 6:4745-54 "Relationship between c-erbB-2 and Other Tumor Characteristics in Breast Cancer Prognosis"
		Foekens et al., 1994, <i>Br. J. Cancer</i> , 70:1217-23 "Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer"
		Foekens et al., July 2001, <i>Cancer Res.</i> , 61:5407-14 "High Tumor Levels of Vascular Endothelial Growth Factor Predict Poor Response to Systemic Therapy in Advanced Breast Cancer"
		Frasor et al., Oct. 2003, <i>Endocrinology</i> , 144:4562-74 "Profiling of Estrogen Up- and Down-Regulated Gene Expression in Human Breast Cancer Cells: Insights into Gene Networks and Pathways Underlying Estrogenic Control of Proliferation and Cell Phenotype"
		GenBank GEO, 11 March 2002, XP002293987 (Abstract) "Affymetrix GeneChip Human Genome U95 Set HG-U95A"
		Gruvberger et al., Aug. 2001, <i>Cancer Res.</i> , 61:5979-84 "Estrogen Receptor Status in Breast Cancer Is Associated with Remarkably Distinct Gene Expression Patterns"
		Hayward et al., Mar. 1977, <i>Cancer</i> , 39:1289-94 "Assessment of Response to Therapy in Advanced Breast Cancer"
		Holloway, et al., 2002, <i>Gynecol. Oncol.</i> , 87:8-16 "Association between <i>in Vitro</i> Platinum Resistance in the EDR Assay and Clinical Outcomes for Ovarian Cancer Patients"
		Hyman et al., Nov. 2002, <i>Cancer Res.</i> , 62:6240-5 "Impact of DNA Amplification on Gene Expression Patterns in Breast Cancer"
		Iacobuzio-Donahue, et al., Sept. 2002, <i>Cancer Res.</i> , 62:5351-7 "The Desmoplastic Response to Infiltrating Breast Carcinoma: Gene Expression at the Site of Primary Invasion and Implications for Comparisons between Tumor Types"
		Jansen et al., 2003, <i>Breast Cancer Research and Treatment</i> , 82:1 p. S14 "Molecular classification of tamoxifen-responsive and -resistant breast carcinomas by gene expression profiling."
		Jansen et al., Feb. 2005, <i>J. of Clin. Oncology</i> , 23(4):732-740 "Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling"
		Jones et al., May 2004, <i>Cancer Res.</i> , 64:3037-3045 "Expression Profiling of Purified Normal Human Luminal and Myoepithelial Breast Cells: Identification of Novel Prognostic Markers for Breast Cancer"

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

Date E-filed: June 1, 2007

Sheet 3 of 4

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 09424.0238USWO	Application Number: 10/581,611
	Applicant: BERNs et al.	
	Filing Date: June 5, 2006	Group Art Unit: Unknown

	Jordan, Mar. 2003, <i>Nt. Rev. Drug Discov.</i> , 2:205-13 "Tamoxifen: A Most Unlikely Pioneering Medicine"
	Kaplan and Meier, 1958, <i>J. Am. Assoc.</i> , 53:457-481 "Nonparametric Estimation From Incomplete Observations"
	Klijn et al., 2002, Ingle WRMaJN (ed): <i>Endocrine Therapy in Breast Cancer</i> , NNY Marcel Dekker "Other Endocrine and Biological Agents in the Treatment of Advanced Breast Cancer"
	Lipton et al., May 2003, <i>J. Clin. Oncol.</i> , 21(10):1967-72 "Scrum <i>HER-2/neu</i> and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen"
	Los et al., 2002, <i>Cytometry</i> , 47:66-71 "Using mRNA Expression Profiling to Determine Anticancer Drug Efficacy"
	Ma et al., June 2004, <i>Cancer Cell</i> , 5(6):607-16 "A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen"
	Mackay et al., 2003, <i>Oncogene</i> , 22:2680-8 "cDNA microarray analysis of genes associated with <i>ERBB2</i> (<i>HER2/neu</i>) overexpression in human mammary luminal epithelial cells"
	Mandlekar et al., 2001, <i>Apoptosis</i> , 6(6):469-77 "Mechanisms of tamoxifen-induced apoptosis"
	Martens et al., 2003, <i>Thromb. Haemost.</i> , 89:393-404 "Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression"
	Osborne, Nov. 1998, <i>N. Engl. J. Med.</i> , 339(22):1609-18 "Tamoxifen in the Treatment of Breast Cancer"
	Osborne, July 2000, <i>Cancer Res.</i> , 60:3706-12 "A Genome-wide Map Showing Common Regions of Loss of Heterozygosity/Allelic Imbalance in Breast Cancer"
	Paik et al., 2003, <i>Breast Cancer Res. Treat.</i> , 82:S10 "Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients—NSABP studies B-20 and B-14."
	Pusztai et al., July 2003, <i>Clin. Cancer Res.</i> , 9:2406-15 "Gene Expression Profiles Obtained from Fine-Needle Aspirations of Breast Cancer Reliably Identify Routine Prognostic Markers and Reveal Large-Scale Molecular Differences between Estrogen-negative and Estrogen-positive Tumors"
	Ravdin et al., Aug. 1992, <i>J. Clin. Oncol.</i> , 10(8):1284-91 "Prognostic Significance of Progesterone Receptor Levels in Estrogen Receptor-Positive Patients With Tamoxifen: Results of a Prospective Southwest Oncology Group Study"

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

Date E-filed: June 1, 2007

Sheet 4 of 4

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 09424.0238USWO	Application Number: 10/581,611
	Applicant: BERNIS et al.	
	Filing Date: June 5, 2006	Group Art Unit: Unknown

		Robertson et al., 1997, <i>Eur. J. Cancer</i> , 33(11):1774-9 "The Clinical Relevance of Static Disease (No Change) Category for 6 Months on Endocrine Therapy in Patients with Breast Cancer"
		Sreekumar et al., Dec. 2002, Biotecchniques Eaton Publishing, Natick US pp. 46-53 Using Protein Microarrays to Study Cancer"
		Tang et al., 2004, <i>Nucleic Acids Res.</i> , 32 Database issue:D533-6 "ERGDB: Estrogen Responsive Genes Database"
		van't Veer et al., Jan. 2002, <i>Nature</i> , 415:530-6 "Gene expression profiling predicts clinical outcome of breast cancer"
		Weigelt et al., Dec. 2003, <i>Proc. Natl. Acad. Sci., U.S.A.</i> , 100(26):15901-5 "Gene expression profiles of primary breast tumors maintained in distant metastases"
		Wright et al., Apr. 1989, <i>Cancer Res.</i> , 49:2087-90 "Expression of c-erbB-2 Oncoprotein: A Prognostic Indicator in Human Breast Cancer"
		Yang et al., 2002, <i>Nucleic Acids Res.</i> , 30(4):e15 "Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation"

23552

PATENT TRADEMARK OFFICE

EXAMINER /Diana B. Johannsen/	DATE CONSIDERED 03/25/2010
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	